COPD Sheep Trial
During 2020, completion of a pilot study indicated the compound has significant pharmaceutical properties to treat chronic obstructive pulmonary diseases (COPD) & other inflammatory indications. This study led to the undertaking of a larger cohort study, to provide the statistical data required to support the earlier study.
The conclusive results of this trial prove beyond doubt the earlier findings. “The strong & significant data derived from this study is consistent with the compound being bioactive & improving key disease parameters in the animal model setting. The striking anti-inflammatory & modest anti-remodeling effects of the compound’s administration were likely linked to its ability to improve lung pathology & functional compliance. The study gives confidence for the future advancement of this drug towards human clinical trials”.
Ethics Approval - Human Cognitive Trial
Another achievement has been gaining Ethics approval for a larger cohort study into cognitive function, which is a broad term that refers to mental processes involved in the acquisition of knowledge, manipulation of information, & reasoning. Cognitive functions include the domains of perception, memory, learning, attention, decision making, & language abilities. Several other clinical evaluations have proven the ability of the compound, GA172, to cross-the-blood-brain-barrier & breakdown beta-amyloid & tau, which is associated with neuro-degenerative diseases – Alzheimer’s, dementia, & others.
TeleScope™ diagnostic technologies
From initial concept, this project has already advanced to accurately detect parasite ova & larvae with >98% accuracy. These exciting proof-of-concept data have led to the generation of a collaborative proposal with experts from the Department of Computer Science & Software Engineering, Swinburne University of Technology. The major aims of this project are to continue immediately to include:
Securing intellectual property around a novel algorithm - software platform & new scientific techniques.
Development of a viable ‘next generation’ veterinary diagnostics system for parasite identification & enumeration. Human markets to follow.
The latest technologies are being incorporated within these undertakings, which enhances this project into being of significant value to the company.
Expressions of interest are being sought with a view to entering into commercial terms for access & use of this ‘disruptive innovative’ technology.
GRETALS is currently involved in many other projects,
that due to confidentiality agreements we are unable to share at this time.
